Hugendubel.info - Die B2B Online-Buchhandlung 

Merkliste
Die Merkliste ist leer.
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.
Einband grossDiscontinuing Antidepressant Medications
ISBN/GTIN

Discontinuing Antidepressant Medications

E-BookEPUBDRM AdobeE-Book
200 Seiten
Englisch
Oxford University Presserschienen am21.10.2021
One in six people in the US are currently taking psychotropic drugs. In 80% of cases, the medication is taken for long-term use and predominantly involves new-generation antidepressants, such as SSRIs (e.g. paroxetine) and SNRIs (e.g. venlafaxine). When patients want to stop taking these drugs and/or their physicians decide it is time for them to stop, substantial problems often can ensue. About 50% of patients experience withdrawal symptoms that do not necessarily subside after a few days or weeks and may be severe and debilitating. Physicians often do not know what to do in these situations. As a result, patients experiencing the anguish and mental pain of withdrawal syndromes are unlikely to receive appropriate medical attention. Discontinuing antidepressants is a highly technical challenge that requires specific strategies. This handbook guides clinicians through each clinical step (assessment; what the counter-indications would be for stopping or continuing; and how discontinuation can best be achieved). It provides a detailed account of the assessment and management strategies, with many case illustrations and clinical examples, drawing from the literature that is available and the extensive personal experience of the author.mehr
Verfügbare Formate
TaschenbuchKartoniert, Paperback
EUR50,50
E-BookEPUBDRM AdobeE-Book
EUR27,99
E-BookPDFDRM AdobeE-Book
EUR27,99

Produkt

KlappentextOne in six people in the US are currently taking psychotropic drugs. In 80% of cases, the medication is taken for long-term use and predominantly involves new-generation antidepressants, such as SSRIs (e.g. paroxetine) and SNRIs (e.g. venlafaxine). When patients want to stop taking these drugs and/or their physicians decide it is time for them to stop, substantial problems often can ensue. About 50% of patients experience withdrawal symptoms that do not necessarily subside after a few days or weeks and may be severe and debilitating. Physicians often do not know what to do in these situations. As a result, patients experiencing the anguish and mental pain of withdrawal syndromes are unlikely to receive appropriate medical attention. Discontinuing antidepressants is a highly technical challenge that requires specific strategies. This handbook guides clinicians through each clinical step (assessment; what the counter-indications would be for stopping or continuing; and how discontinuation can best be achieved). It provides a detailed account of the assessment and management strategies, with many case illustrations and clinical examples, drawing from the literature that is available and the extensive personal experience of the author.
Details
Weitere ISBN/GTIN9780192651310
ProduktartE-Book
EinbandartE-Book
FormatEPUB
Format HinweisDRM Adobe
FormatE101
Erscheinungsjahr2021
Erscheinungsdatum21.10.2021
Seiten200 Seiten
SpracheEnglisch
Dateigrösse1137 Kbytes
Artikel-Nr.8126742
Rubriken
Genre9200

Autor

Giovanni Andrea Fava , MD, is currently Clinical Professor of Psychiatry at the University of Buffalo, State University of New York. He has authored more than 500 scientific papers on depression, psychotherapy, psychopharmacology and psychosomatic medicine. He has introduced a novel psychotherapeutic approach (Well-Being Therapy. Basel, Karger, 2016), the sequential model for combining pharmacotherapy and psychotherapy, the concept of staging in psychiatry, the Diagnostic Criteria for Psychosomatic Research, and new methods of psychiatric evaluation. He is also editor-in-chief of the top journal Psychotherapy and Psychosomatics. As an investigator, he has published groundbreaking research on antidepressant drug discontinuation . As an editor, he has published key papers that have suggested a reconsideration of the problem and modification of the guidelines.